Leukemia and Lymphoma Society
Eilean Therapeutics to Evaluate FLT3 Inhibitor Lomonitinib in Beat AML Trial
The lomonitinib arm will include patients with FLT3-mutated relapsed or refractory acute myeloid leukemia.
The group is betting that a master protocol design and new trial matching technology can accelerate progress where there has been little.
Leukemia and Lymphoma Society Launches Master Protocol Trial in Childhood Leukemia
A genomic eligibility algorithm developed for the study will allow researchers to match patients to appropriate therapy trials.
The Leukemia & Lymphoma Society has built remote-friendly technologies into the Beat AML trial, which they hope will influence future precision oncology umbrella studies.
Leukemia & Lymphoma Society Wins $100K From Press On Fund for Pediatric Precision Oncology Trial
The goal of the LLS PedAI study is to investigate the efficacy and safety of multiple precision oncology drugs at once for children with relapsed acute leukemia.